Communiqués Newron Pharmaceuticals S.p.A. Xetra

Actions

NP5

IT0004147952

Recherche biotechnologique et médicale

Marché Fermé - Xetra Autres places de cotation 17:35:58 07/08/2026			Varia. 5j.	Varia. 1 janv.
13,20 ^EUR	-0,75%		+2,33%	-49,91%

03/07	Newron Pharmaceuticals va modifier l'essai de phase 3 de son traitement contre la schizophrénie	MT
05/05	Edison ne s'inquiète pas outre mesure de la suspension d'un essai

Communiqués

02/07	Newron Provides Update Following Type A Meeting With the FDA	BU
28/05	Newron Pharmaceuticals to Participate in June Investor Conferences	BU
29/04	Newron Pharmaceuticals S p A : reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study	PU
29/04	Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study	BU
23/04	Newron announces AGM 2026 results	EQ
30/03	Newron Pharmaceuticals S p A : Report (SIRS 2026)	PU
24/03	Newron Presents 2025 Financial Results and Provides 2026 Outlook	BU
24/03	Newron presents 2025 financial results and provides 2026 outlook	EQ
24/03	Newron Pharmaceuticals S p A : presents 2025 financial results and provides 2026 outlook	PU
20/03	Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)	BU
20/03	Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)	EQ
19/03	Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract	BU
19/03	Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract	EQ
19/03	Newron Pharmaceuticals S p A : announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract	PU
18/03	Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting	BU
18/03	Newron announces nominations to its Board of Directors at upcoming Annual General Meeting	EQ
16/02	Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program	EQ
16/02	Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program	BU
03/02	Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia	BU
03/02	Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia	EQ
14/01	Newron Pharmaceuticals S p A : Report (vL Flash Update JAN26)	PU
07/01	EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan	BU
07/01	Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan	EQ
06/01	Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent	BU
06/01	Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent	EQ